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Intracellular accumulationThe spreading of pathology through neuronal pathways is likely to be the cause of the progressive cognitive loss
observed in Alzheimer's disease (AD) and other neurodegenerative diseases. We have recently shown the prop-
agation of AD pathology via cell-to-cell transfer of oligomeric amyloid beta (Aβ) residues 1–42 (oAβ1–42) using
our donor–acceptor 3-D co-culture model. We now show that different Aβ-isoforms (ﬂuorescently labeled 1–
42, 3(pE)-40, 1–40 and 11–42 oligomers) can transfer from one cell to another. Thus, transfer is not restricted
to a speciﬁc Aβ-isoform. Although different Aβ isoforms can transfer, differences in the capacity to clear and/or
degrade these aggregated isoforms result in vast differences in the net amounts ending up in the receiving
cells and the net remaining Aβ can cause seeding and pathology in the receiving cells. This insufﬁcient clearance
and/or degradation by cells creates sizable intracellular accumulations of the aggregation-prone Aβ1–42 isoform,
which further promotes cell-to-cell transfer; thus, oAβ1–42 is a potentially toxic isoform. Furthermore, cell-to-cell
transfer is shown to be an early event that is seemingly independent of later appearances of cellular toxicity. This
phenomenon could explain how seeds for the AD pathology could pass on to new brain areas and gradually in-
duce AD pathology, even before the ﬁrst cell starts to deteriorate, and how cell-to-cell transfer can act together
with the factors that inﬂuence cellular clearance and/or degradation in the development of AD.
© 2014 The Authors. Published by Elsevier Inc.Open access under CC BY-NC-ND license. Introduction
Multiple lines of evidence have established that toxic aggregates and
depositions of amyloid beta (Aβ) peptides play key roles in the pathol-
ogy of Alzheimer's disease (AD;Hardy and Selkoe, 2002). Recent studies
have found that the presence of soluble forms of Aβ oligomers corre-
lates better with cognitive impairment and synaptic dysfunction than
the presence of insoluble deposits (Brouillette et al., 2012; Selkoe,
2008). Experimental evidence has shown that soluble Aβ oligomers –
both extracellular (Benilova et al., 2012) and intracellular (Gouras
et al., 2010; LaFerla et al., 2007;Wirths et al., 2001) – play an important
role in AD pathology. Neurotoxicity associated with intracellular accu-
mulation of soluble Aβ oligomers has been reported as an early event
in AD and may be responsible for synaptic dysfunction (Klein et al.,ect.com).
. Open access under CC BY-NC-ND lice2001). These accumulations could come from either Aβ produced intra-
cellularly (Wirths et al., 2001) or Aβ internalized from the extracellular
space (Nath et al., 2012). The accumulation of intracellular Aβ can be
transferred from one cell to a connected cell, whichmay lead to gradual
pathological progression in AD (Nath et al., 2012). Similar prion-like
propagation capacities have been suggested for other neurodegenera-
tive proteins, such as α-synuclein and tau (Clavaguera et al., 2009;
Desplats et al., 2009). The mechanisms involved in this transfer are
not yet understood. However, these previous studies on cell-to-cell
transfer with different neurodegenerative aggregates suggest that the
endosomal–lysosomal pathway or the lysosomal exocytosis process
may be involved in the transfer mechanism.
Aging is themain risk factor for sporadic AD; it is linked to the grad-
ual dysfunction of the degradation systems, thus causing the cellular ac-
cumulation of various proteinaceous aggregates (Villeda et al., 2011).
Reduced lysosomal and proteosomal degradation efﬁciencies have
also been associated with AD progression because they may lead to
intraneuronal accumulations of Aβ aggregates (Agholme et al., 2012;
Nixon et al., 2008; Zheng et al., 2011). Additionally, defective Aβ-
degrading enzymes and aberrant clearance processes of lipoproteins,
ApoE, and low-density lipoprotein receptors play crucial roles in thense. 
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creased degradation and/or clearance of Aβ are involved in the toxic ac-
cumulation and cytotoxic effects.
Amyloid precursor protein (APP) can be cleaved and processed in
several ways, resulting in Aβ variants that differ in length, cytotoxicity
and proportion in the AD brain. Clinical studies have revealed the exis-
tence of a variety of toxic aggregates of different Aβ isoforms variably
distributed as depositions in the AD brains (Benilova et al., 2012).
Thus, we are interested in whether the reported differences in neuro-
toxicity between different Aβ isoforms could be related to their propen-
sities for cell-to-cell transfer. Furthermore, we wanted to investigate
whether this type of transfer was related to cytotoxicity or cellular deg-
radation and/or clearance of Aβ. Intracellular accumulations of non-
degradable toxic aggregates are important for neurotoxicity. Therefore,
the role of cell-to-cell transfer in the disease progression and its rela-
tionship to cellular clearance and/or degradationmay give fundamental
clues to the etiology of AD.We compared four different Aβ species pres-
ent in the AD brain to cover different parts of the large spectrum of Aβ
variants. The most prevalent Aβ species in the brain is Aβ1–40. Another
variant, Aβ1–42, is less abundant, but it is more cytotoxic; it is also
aggregation-prone, and its proportion rises in the AD brain
(Kuperstein et al., 2010). The toxicity of the N-terminal-truncated
pyro-glutamatemoiety-modiﬁed Aβ3(pE)–40 isoform is almost compara-
ble to the moderately toxic Aβ1–40 isoform (Tekirian et al., 1999). The
non-toxic, unmodiﬁed, N-terminal-truncated Aβ peptide Aβ11–42 (Jang
et al., 2010, 2013) was included as a negative control.
We show that oligomers of different ﬂuorescently labeled Aβ-
isoforms (Aβ1–42; 1–40; 3(pE)–42; 11–42) can transfer from cell to cell. Al-
though different Aβ isoforms can transfer between cells, the inability
to clear and/or degrade more resistant isoforms, such as oligomeric
Aβ1–42 (oAβ1–42), leads to larger net accumulations that could promote
the cell-to-cell transfer. Furthermore, cell-to-cell transfer is an early
event that is seemingly independent of later cellular toxicity. Together,
these phenomena could explain how seeds for AD pathology could
pass on to new brain areas and gradually induce the AD pathology be-
fore the ﬁrst cell starts to die.
Methods
Labeling of Aβ peptides
The synthetic Aβ peptides Aβ11–42 and Aβ3(pE)–40 (Innovagen) were
dissolved in 20 mMHEPES buffer, pH 7.4, and vortexed until completely
dissolved. The solution was added to 6-carboxytetramethylrhodamine
succinimidyl ester (TMR) (Invitrogen), an amine-reactive ﬂuoroprobe,
in amolar ratio of 2:1. The solutionwas vortexed and incubated overnight
at 4 °C. After the incubation, the unbound dye was removed by size-
exclusion chromatography using PD-10 columns (GE Healthcare). The
samples were collected from the column, divided into small aliquots
and freeze-dried. The freeze-dried samples were re-suspended in
1,1,1,3,3,3-hexaﬂuoro-2-propanol (HFIP) and freeze-dried; then, they
were stored at−20 °C. The synthetic Aβ1–42 and Aβ1–40 peptides labeled
with TMR (AnaSpec)were divided into small aliquots by re-suspension in
HFIP and stored at−20 °C following freeze-drying. The labeling percent-
ages were calculated bymeasuring the concentration of TMR at an absor-
bance wavelength of ~550 nm (TMR ε555nm = 65,000 M−1 cm−1
(Haugland, 2001)) and comparing the concentration with the amount
of total protein measured using a Bio-Rad protein assay kit. The percent-
ages of ﬂuoroprobe TMR labeling for the oAβ(1–42; 1–40; 3(pE)–42; 11–42)-
TMR peptides were 23.8%, 7.5%, 3.5% and 5.3%, respectively.
Preparation of oligomers and protoﬁbrils
To obtain oligomers from the freeze-dried peptides, the lyophilized
Aβ variants were dissolved in dimethyl sulfoxide (DMSO) to 1.5 mM
and immediately vortexed. Then, the solution was diluted to 100 μMusing 20 mMHEPES buffer and sonicated for 2 min. The sonicated sam-
pleswere incubated at 4 °C for 24 h, causing the formation of oligomers
(Nath et al., 2012).
Protoﬁbrils were prepared using a standard characterized protocol
(Klingstedt et al., 2011). Aβ 1–42-TAMRA was dissolved in 2 mM NaOH
to a concentration of 222 μM. Then, the sample was diluted in PBS to a
ﬁnal concentration of 10 μM and incubated at 37 °C for 7 h.
Transmission electron microscopy (TEM)
Transmission electron microscopy (TEM) was used to characterize
the prepared oligomers. The prepared Aβ oligomers (oAβ) of the re-
spective variants (Aβ1–42; 1–40; 3(pE)–42; 11–42) were diluted to 10 and
30 μM in HEPES buffer and were added to carbon-coated nickel grids,
whichwere incubated for 1 min and blotted with ﬁlter paper. The sam-
pleswere incubatedwith 10 μl of 2% uranyl acetate for 15 s for negative
staining; the gridwas then dried usingﬁlter paper. Theprepared sample
grids were viewed in a JEOL 1230 transmission electron microscope
(Jeol Ltd; Tokyo, Japan), and the images were captured with ORIUS SC
1000 CCD camera.
Differentiation and co-culturing of SH-SY5Y cells
The SH-SY5Y (ECACC; SigmaAldrich) donor cellswere differentiated
as described earlier (Agholme et al., 2010; Nath et al., 2012) using
10 μMretinoic acid (RA; SigmaAldrich). The donor cells were incubated
with either 500 nM or 1 μM of the oAβ-TMR peptides for 3 h at 37 °C.
The cells were then washed twice with PBS for 10 min at 37 °C,
trypsinized, mixed (75,000–100,000 cells) with pre-chilled extracellu-
lar matrix (ECM) gel (Sigma Aldrich) at a 1:1 ratio and reseeded. The
highly differentiated SH-SY5Y acceptor cells were cultured in ECM gel
and differentiated with media that included brain-derived neurotropic
factor (BDNF), neuregulin β1 (NRGβ), nerve growth factor (NGF) and
vitamin D3 (Agholme et al., 2010). After 10 days of differentiation, the
cells were transfected with EGFP-tagged endosomal (Rab5a) or lyso-
somal (lysosomal-associated membrane protein 1, LAMP-1) proteins
using Organelle Lights BacMam-2.0 (Invitrogen) (Nath et al., 2012).
The donor and acceptor cells were co-cultured by adding 75,000
donor cells in ECM gel to 80,000 differentiated acceptor cells on cham-
bered glass slides and incubating them in RA supplemented MEM
media for 24, 48 or 72 h at 37 °C (Nath et al., 2012). The cells were
ﬁxed using 4% paraformaldehyde and mounted using ProLong gold
anti-fade mounting media (Invitrogen) after 24, 48 or 72 h of incuba-
tion. Cell-to-cell transfers also were studied after the addition of
50 nM rapamycin (Fisher Scientiﬁc) in the co-culture media for 24, 48
or 72 h at 37 °C.
Confocal microscopy
Images of ﬁxed cells and live cells were taken using a LSM 700 Zeiss
confocal microscope. The differential interface contrast (DIC) mode and
the red and green channels were used to take the images with 40× oil
plan-apochromatic DICII objectives. Transmitted light was used for
DIC, and 543 nm and 488 nm laser excitation wavelengths were used
to image the red and green channels, respectively.
Analysis of late-endosomal or lysosomal co-localization and degradation of
oligomers
The partially differentiated (10 μM RA for 7 days) SH-SY5Y cells
were incubated with 500 nM of the respective oligomeric Aβ-TMR var-
iant, diluted in P/S (penicillin/streptomycin) and supplemented MEM
media for 3 h at 37 °C. The cells were extensively washed with PBS
(2 × 10 min at 37 °C) and incubated with 200 nM lysotracker green
DND-26 (Invitrogen) for 15 min. Live-cell imaging using confocal mi-
croscopy was performed to determine the amount of internalized
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using the Volocity software (Perkin Elmer).
For degradation analysis, the cells were exposed to the different
oAβ-TMR variants for 3 h, as described above, and were reseeded on
chambered glass slides with ECM gel (80,000 cells/well). The cells
were ﬁxed and mounted after 24, 48 or 72 h of culturing. The areas of
red ﬂuorescent oligomers per cell were analyzed from confocal micro-
graphs by averaging the area from at least 250 cells for each set and
using Volocity software to determine the degradation of the internal-
ized oligomers.
The calculated absolute areas of internalized red oligomers per cell at
0 h for the oAβ-TMR (1–42, 1–40, 3(pE)–40, 11–42) isoforms were
19.34 ± 0.22, 9.98 ± 0.12, 1.07 ± 0.02 and 2.48 ± 0.04 μm2/cells, re-
spectively. The calculated residual intracellular oligomers over time
were normalized as percentages, considering the areas at 0 h as 100%.
Size exclusion chromatography (SEC)
The size exclusion chromatography (SEC) technique was used to
separate monomers, dimers and higher oligomers from the prepared
Aβ1–42TMR oligomer solution. This solution (100 μM) was separated
using a Superdex 75 10/300 GL column (GE Healthcare) equilibrated
in PBS. After protein separation, 500 μl of each fraction was collected.
The areas of the peaks were calculated to obtain quantitative data of
the separated oligomers, dimers and monomers.
Western blot analysis of LAMP-2 expression
The donor cells were prepared from partially differentiated cells
(10 μM RA for 7 days). The cells were incubated with 1 μM of each
oAβ isoform for 3 h and reseeded into a 24-well plate for culturing
with RA medium. The donor cells (100,000) that were internalized
with 1 μM of each oAβ isoform after 24, 48 or 72 h of incubation were
lysed in 0.5 M Tris HCl pH 6.8, which included 1% glycerol and 0.2%
SDS. Cell lysates lacking Aβ were used as controls. Western blots were
performed on the lysed protein samples by loading 10 μg of the samples
into a 4–20% SDS ClearPage gels and using the mouse anti-human
LAMP-2 antibody (SouthernBiotech), which was used at a 1:1000 dilu-
tionwith blocking solution (5% non-fat drymilk). Goat anti-mouse HRP
(Dako)was used at a 1:3000 dilution as a secondary antibody. The load-
ing control was glyceraldehyde 3-phosphate dehydrogenase (GAPDH),
and anti-GAPDH horseradish peroxidase (HRP) antibody (Novus Bio-
logicals) was used in a 1:30,000 dilution.
Cytotoxicity assay and mitochondrial potential measurements with donor
cells
Cell viability assays using XTT (2,3-bis [2-methoxy-4-nitro-5-
sulfophenyl]-5-[(phenylamino) carbonyl]-2H-tetrazolium hydroxide)
and measurements of mitochondrial potential using JC-1 were per-
formed on the donor cells that had internalized 1 μM of either oAβ iso-
form after 24, 48 or 72 h of incubation. Cells lacking Aβ were used as
controls.
The donor cells were added with XTT reagent and electron couple
reagent (Roche) at a ratio of 50:1 to the media after 24, 48 or 72 h of
reseeding. The reduced XTT product produced by mitochondrial en-
zymes in viable cells, formazan (bright orange in color) was measured
after 8 h of incubation at 450 nm and 750 nm using a Victor Wallac
(PerkinElmer) plate reader (Roehm et al., 1991; Scudiero et al., 1988).
The donor cells were incubated for 10 min with 5 μM JC-1
(Invitrogen) enriched serum free medium for themitochondrial poten-
tial assay. Subsequent to the JC-1 incubation, the cells were washed
twice in PBS and trypsinized. The cells were then resuspended in ice-
cold PBS and ﬁltered through a 30-μm mesh. The cells were brieﬂy
vortexed and then directly analyzed using a Calibur ﬂow cytometer(equipped with a 488–514 nm argon laser) and the CellQuest Pro soft-
ware (Becton Dickinson).
Statistical analysis
Thedata from the area analysiswere expressed in themeans ± SEM
(standard errors of the mean) to represent the vast variation of the ac-
cumulated areas of the oligomers and the lysosomes. The other data
were represented by the means ± SD (standard deviations). Hypothe-
sis testswere calculated using a two-tailed unpaired Student's t-tests for
the size distribution of lysosomes or one-way analyses of variance
(ANOVAs) for evaluation of co-localization; the signiﬁcance level was
p b 0.05. Pearson's correlation was used for correlation analysis using
GraphPad Prism software. Each batch of cell cultures represented one
independent experiment (n = 1).
Results
Characterization of the oAβ isoforms
The prepared oligomers of the Aβ-TMR (1–42, 1–40, 3(pE)–40 and
11–42) isoforms were characterized. The TEM images showed that the
samples consisted primarily of spherical oligomers (Fig. 1) without ﬁ-
brils or proto-ﬁbrils. The aggregation-prone Aβ1–42TMR isomer formed
larger oligomers of average diameter 42 ± 27 nm (Fig. 1A) compared
to the oligomers of the relatively less aggregation-prone Aβ-TMR iso-
forms (1–40, 3(pE)–40 and 11–42) which had an average diameter of
24 ± 9 nm (Figs. 1B–D). Size exclusion chromatography (SEC) separa-
tion using Superdex 75 10/300 GL conﬁrmed the formation of oligomers
for all four isoforms. The oligomers of the respective isoformswere elut-
ed at the void volume (MW N 70,000 Da) during the separation. The
TMR ﬂuorescence tags on the Aβ isoforms had no signiﬁcant effects on
oligomerization. In accordance with our previous data, oligomer forma-
tion and toxicity were similar compared to unlabeled oAβ1–42 samples
(Nath et al., 2012).
Cell-to-cell transfer of oligomeric Aβ-isoforms
The cell-to-cell transfer properties of the different oAβ-TMR isoforms
were compared using the same donor–acceptor co-culturing method
(Fig. 2A) as in previous studies (Nath et al., 2012). All of the investigated
isoforms transferred, with very different net amounts. The results re-
vealed that the oAβ1–42TMR and oAβ3(pE)–40TMR isomers were trans-
ferred from the donor cells to the connected green acceptor cells,
resulting in a considerable net amount (Fig. 2B). However, only a few of
the connected acceptor cells (b5%) co-cultured with the oAβ1–40TMR-
and oAβ11–42TMR-containing donor cells showed low-intensity, discrete
red ﬂuorescent spots that were distinguishable from auto-ﬂuorescence
(Fig. 2B). The presence of transferred red oligomeric isoforms in the ac-
ceptor cells that were connected to donor cells was quantiﬁed by
counting several confocal images (at least 10 from each set) (Fig. 2C).
The percentage of connected acceptor cells with transferred oAβ1–
42TMR increased with time of incubation, while oAβ3(pE)–40TMR started
to decrease at 72 h, following an initial increase at 48 h. The results sug-
gest that transfer is not speciﬁc to any one Aβ isoform. All of the exam-
ined isoforms can transfer from donor cells to acceptor cells; however,
the more aggregation-prone isoform oAβ1–42TMR caused large intracel-
lular accumulations in the acceptor cells.
Degradation and/or clearance of oAβ-TMR isoforms and concomitant
variation in cell-to-cell transfer
The disappearance of the internalized oAβ-TMR isoforms was ana-
lyzed over time using oAβ-TMR-fed donor cells incubated with the dif-
ferent oAβ-TMR isoforms and then extensively washed and reseeded.
The 0 h donor cells were collected immediately after the oAβ-TMR
Fig. 1. Characterizations of oAβ isoforms. (A–D) Transmission electronmicroscopy (TEM) images show that (A) Aβ1–42TMR, (B) Aβ1–40TMR, (C) Aβ3(pE)–40TMR and (D) Aβ11–42TMR form
mainly spherical oligomers during oligomer preparation. No ﬁbrils were detected by EM. The aggregation-prone Aβ1–42TMR isoform showed formation of larger-sized oligomers com-
pared to the relatively less aggregation-prone Aβ(1–40, 3(pE)–40, 11–42)TMR isoforms. A layer of oligomers was applied on a copper grid using 10 μl of 10 μM solutions of Aβ1–42TMR and
Aβ1–40TMR. For the Aβ3(pE)–40TMR and Aβ11–42TMR isoforms, 10 μl of 30 μM solutions was used. Scale bars A = B = C = D = 200 nm; n = 3.
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areas of internalized red oligomers per donor cell after 0, 24, 48 and
72 h were analyzed from confocal images (Fig. 3A) using the Volocity
software to obtain the intracellular accumulations of the oAβ-TMR iso-
formsover time (Fig. 3B). The results revealed that only 10% of the inter-
nalized oAβ1–42TMR isoform had disappeared after 72 h. However, the
cells managed to degrade and/or clear 53% of oAβ3(pE)–40TMR after
72 h of incubation. The isoforms oAβ1–40TMR and oAβ11–42TMR almost
disappeared completely relative to the above two isoforms: 96% of
oAβ1–40TMR and most of oAβ11–42TMR were cleared even before 48 h
(Fig. 3B). Both degradation (Nixon et al., 2008) and clearance (Deane
et al., 2008) have been described as mechanisms for expunging Aβ,
and both mechanisms have been suggested to be involved in AD etiolo-
gy. Further studies will be needed to clarify which of thesemechanisms
are responsible for the currently described reduction of Aβ oligomers.
The percentage of intracellularly accumulated oligomer for each iso-
form had a highly signiﬁcant, linear Pearson's correlation (r = 0.889,
p = 0.001) with the amount of cell-to-cell transfer over time (Fig. 3C).
The highly signiﬁcant linear correlation suggests that the inability to
clear and/or degrade oAβ and subsequent intracellular accumulations
could enhance the net amount of cell-to-cell transfer. The isoform
oAβ1–42TMR showed abnormal intracellular accumulations and consid-
erable cell-to-cell transfer over time compared to oAβ3(pE)–40TMR,
oAβ1–40TMR and oAβ11–42TMR, which were more readily cleared and/
or degraded by cells. It is plausible that these intracellular accumula-
tions of oAβ1–42TMR promote cell-to-cell transfer, compared to
oAβ3(pE)–40TMR, oAβ1–40TMR and oAβ11–42TMR isoforms which are less
prone to accumulate intracellularly.
The involvement of lysosomal degradation was further investigated
using rapamycin, an autophagy inducer. These experiments show lower
accumulation (near signiﬁcance at 48 h, signiﬁcant at 72 h) and a ten-
dency to decrease cell-to-cell transfer (not reaching statistical signiﬁ-
cance) of oAβ1–42TMR in the presence of 50 nM rapamycin compared
to control (without rapamycin) over days (Figs. 3D–E). The transfer to
the acceptor cell is secondary to the accumulation in the donor cells.
Since the non-toxic level of rapamycin only results in a partial lower ac-
cumulation of oAβ1–42TMR in the donor cells, any change in the cell-to-
cell transfer is expected to be small. However, the trend towards de-
creased oAβ transfers seen after rapamycin treatment supports a role
of the lysosomal system in the net amount of cell-to-cell transfer.Intracellular internalization of oAβ-TMR isoforms and their co-localization
within late-endosomes/lysosomes
Previous studies have shown that oligomers of Aβ1–42 and Aβ1–40
spontaneously internalize and accumulate in the late-endosomal/
lysosomal vesicles after extracellular administration (Hu et al., 2009;
Nath et al., 2012). The intracellular internalization and co-localization
in late-endosomes/lysosomes of extracellularly applied oAβ-TMR iso-
forms was analyzed after 3 h of incubation using live-cell confocal mi-
croscopy (Fig. 4A). The accumulation of oligomers in late-endosomes/
lysosomes was quantiﬁed by determining the percentage of co-
localization using both the overlap coefﬁcient and global Pearson's cor-
relation between the red ﬂuorescent oAβ-TMR isoforms and the green
lysotracker-labeled vesicleswith Volocity software (Fig. 4B). The results
from a one-way ANOVA test revealed that there was no signiﬁcant dif-
ference (p N 0.05) in the percentage of co-localization of oligomers
with lysotracker between the four different oAβ-TMRs. However,
oAβ1–42TMR caused abnormal intracellular accumulation in donor
cells and extra-large late-endosomal/lysosomal vesicles over time.
Such vesicle structures were not observed after incubation with
oAβ3(pE)–40TMR, oAβ1–40TMR or oAβ11–42TMR, which could be cleared
with time (Fig. 4C).
Abnormal lysosomal morphology in oAβ1–42-TMR accumulated cells
Several studies have described the failure of the lysosomal degrada-
tion pathway in Aβ-peptide-associated AD pathology (reviewed in
Nixon et al. (2008)). The accumulation of non-degradable Aβ peptides
and abnormal lysosomal morphology in the axonal compartment has
also been reported (Lee et al., 2011b). In the present study, the donor
and acceptor cells with internalized oAβ1–42TMR exhibited larger
lysosomes over time (Figs. 4C, 5A). The sizes of the oAβ1–42TMR-
accumulated lysosomal vesicles in the acceptor cells suggest pathological
changes following cell-to-cell transfer. Therefore, the changes in lysosom-
al areas (EGFP-tagged green lysosomal LAMP-1 protein) over time were
determined by comparing the sizes before transfer (considered to be
0 h) and after oAβ-TMR transfer in acceptor cells. The vesicles were seg-
regated into small (0–0.75 μm2), medium (0.76–1.50 μm2), large (1.51–
5 μm2) and extra-large vesicles (N5 μm2) based on the standard areas
of lysosomes (Bains and Heidenreich, 2009). There was a signiﬁcant
Fig. 2.Cell-to-cell transfer of oligomeric Aβ isoforms. (A)A cartoon illustrating the 3D co-culturemodelwith differentiated SH-SY5Y cells employed tomeasure the transfer of the TMR-tagged
red ﬂuorescent Aβ peptides (1–40, 3(pE)–40, 11–42 and 1–42). The co-culture model consists of two cell populations seeded in ECM gel, in which one population has internalized red Aβ-
TMR conjugates (donor cells) while the other expresses green GFP-tagged endo/lysosomal proteins (acceptor cells), allowing us to detect positive transfer between the two. (B) Superim-
position of red, green and DIC confocal images shows the transfer of oAβ isoforms (red) between the donor cells (internalized with 500 nM oAβ isoforms) and the connected acceptor
cells (green). Arrows indicate the transferred oligomers in the acceptor cells connected to donor cells. Scale bar = 10 μm. (C) Quantiﬁcation of the connected acceptor cells with successfully
transferred Aβ isoforms over time. Signiﬁcantly higher numbers of acceptor cells were observed to contain oAβ1–42 and oAβ3(pE)–40 isoforms compared to cells with oAβ1–40 and oAβ11–42
isoforms. Data are represented as the means ± SD; n = 4.
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transfer compared to the vesicle sizes detected at 0 h (Fig. 5B). The
mean area of lysosomal vesicles was also signiﬁcantly increased over
time in acceptor cells containing transferred oAβ1–42TMR (Fig. 5C). A sig-
niﬁcant number of lysosomes with accumulated red ﬂuorescent oligo-
mers showed abnormal morphology and vesicle areas greater than
20 μm2 (Fig. 5A). The lysosomes did not show any prominent changes
in their structures when exposed to the less aggregation-prone oAβ iso-
forms (1–40 and 11–42) (data not shown). After exposure to themoder-
ately degradable isoform oAβ3(pE)–40, medium- and large-sized vesicles
appeared over time (Fig. 5A), but no signiﬁcant change in the number
of extra-large-sized lysosome vesicles was observed (data not shown).
Similarly, abnormal accumulation-associated increases in the size of late
endosomes/lysosomes were observed in the donor cells that had inter-
nalized oAβ1–42TMR (Fig. 4C).The accumulation of the toxic oligomers of Aβ1–42 can activate differ-
ent autophagy pathways (Nixon et al., 2008). Furthermore, autophagy-
associated lysosomal protein LAMP-2 activity has also been reported to
increase under different stress conditions, including oxidative stress,
prolonged starvation or exposure to toxic compounds (Cuervo and
Dice, 2000; Saftig and Eskelinen, 2008). Hence, the LAMP-2 expression
levels were studied over time in relation to the accumulation of non-
degradable oAβ-TMR isoforms, particularly oAβ1–42TMR. Quantiﬁcation
by Western blot revealed a signiﬁcant increase in LAMP-2 protein 72 h
after oAβ1–42TMR internalization in donor cells (Fig. 5D). Separation of
the acceptor cells receiving transfer from the co-culture is technically dif-
ﬁcult, and abnormal lysosomes were evident in oAβ1–42TMR-treated
donor and acceptor cells over time (Figs. 4C and 5A). Therefore, LAMP-
2 quantiﬁcations were performed with donor cells. Other oAβ isoforms
(3(pE)–40, 1–40 and 11–42) did not show any signiﬁcant LAMP-2
Fig. 3. Degradation of internalized oligomeric Aβ-isoforms. (A) Confocal images show residual oAβ-TMR isoforms (red) 24, 48 and 72 h after internalization. Donor cells were incubated with 500 nM oAβ-TMR isoforms for 3 h for oligomer inter-
nalization. Scale bar = 10 μm; n = 4. (B) Analysis of the confocal images using Volocity software revealed that Aβ1–42 exhibited the greatest resistance (signiﬁcantly higher compared to Aβ11–42) to clearance and/or degradation, followed by
Aβ3(pE)–40, while Aβ1–40 and Aβ11–42 were almost completely cleared and/or degraded at 24 and 48 h, respectively. Data were calculated from ~250 cells for each isoform and are represented as the means ± SEM; n = 4. (C) When comparing
the numbers of acceptor cells with transferred Aβ isoforms at 24, 48 and 72 h with corresponding residual internalized oligomers in donor cells, an inverse correlation was revealed (Pearson's correlation coefﬁcient, r = −0.889, p = 0.001).
(D) Analysis of oAβ1–42 in donor cells shows a decrease of accumulation with rapamycin (50 nM) compared to without. Data were analyzed from confocal images of ~250 cells for each data point and are represented as the means ± SEM;
n = 2. (E) Cell-to-cell transfers of oAβ1–42were quantiﬁed counting the connected acceptor cellswith successfully transferred oAβ1–42 over time. There is a trend towards decreased net amount of oAβ1–42 but this did not reach statistical signiﬁcance.
Data represented as the means ± SD; n = 2. Statistical signiﬁcance was evaluated using a two-tailed unpaired Student's t test. *p b 0.05, **p b 0.01 and ***p b 0.001.
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Fig. 4. Internalized Aβ co-localizes with lysosomes. (A) Superimposition of red, green and DIC confocal images shows oAβ-TMR isoforms (red), lysotracker-labeled late-endosomes/
lysosomes (green) and co-localization (yellow) in differentiated SH-SY5Y cells. Images were taken after 3 h incubation of cells with 500 nM oAβ-TMR isoforms and thorough washing.
Scale bar = 10 μm. (B) Mean overlap coefﬁcients of co-localization of the oAβ isoforms (1–42, 3(pE)–40, 1–40 and 11–42) with lysotracker were calculated. No signiﬁcant differences
(p N 0.05, n = 3) were revealed (one-way ANOVA test). (C) Late-endosomes/lysosomes (green lysotracker) internalized with oAβ1–42 in donor cells showed the formation of extra-
large vesicles over time (48 h shown). Arrows indicate oligomers internalized in extra-large late-endosomes/lysosomes. Scale bar = 5 μm; n = 3.
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sult suggests that lysosomal accumulation by degradation-resistant
oAβ1–42TMR isoforms could induce intra-lysosomal stress-like be-
havior over time, while no similar effects were evident for more de-
gradable Aβ isoforms.
Effects of monomers, dimers, oligomers and protoﬁbrils of Aβ1–42TMR on
cell-to-cell transfer
The prepared oligomers of Aβ1–42 TMR are a mixture of monomers,
dimers and different sizes of other oligomers. To identify which of thespecies accumulate in the lysosome, the prepared oligomers were iso-
lated using SEC (Fig. 6A). The puriﬁedmonomers, dimers and oligomers
showed considerable internalization in donor cells when donor cells
were incubated with 500 nM of Aβ1–42TMR species for 3 h. The dimers
and oligomers were transferred from donor to acceptor cells, and puri-
ﬁed monomers were also detected in cell-to-cell transfer. The extra-
large lysosomes accumulated with Aβ1–42TMR had signiﬁcantly fewer
monomers compared to oligomers and dimers in the transferred accep-
tor cells (Figs. 6B, C).
Furthermore, the effects of protoﬁbrils were studied. The EM images
showed that the prepared protoﬁbrils of Aβ1–42TMR are a mixture of
Fig. 5. Lysosomal alterations. The degradation resistance exhibited by oligomeric Aβ1–42 induced a lysosomal stress-like behavior. (A) Confocal images showed the formation of abnor-
mally extra-large lysosomal vesicles (white arrow) in the Aβ1–42 transferred acceptor cells. While the other isoforms did not show extra-large lysosomes, a few medium- and large-
sized lysosomes were visible in the Aβ3(pE)–40 transferred acceptor cells (black arrow). Scale bar = 5 μm; n = 4. (B, C) Confocal images were analyzed, and the distributions (B) and
mean sizes (C) of the lysosome vesicles were determined in acceptor cells subsequent to receiving oAβ1–42. Data were calculated from ~50 cells for each isoform and are represented
as the means ± SD for distribution, but means ± SEM were used to represent mean size because of the vastly variable vesicle sizes; n = 6. (D) Quantiﬁcation of lysosome-associated
membrane protein 2 (LAMP-2) with Western blot revealed a signiﬁcant increase after 72 h of Aβ1–42 internalization in donor cells; n = 3. (E) Aβ isoforms 3(pE)–40, 1–40 and 11–42
did not show any signiﬁcant increases in LAMP-2 expression after 72 h. The 0 h time point represents internalization of oAβ-TMR isoforms after 3 h incubation of donor cells with
1 μM oligomeric solutions and thorough washing; n = 3.
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disappeared signiﬁcantly (85–91%) in donor cells after 48 h (Fig. 6E)
and cell-to-cell transfer was signiﬁcantly lower (17.2 ± 16%) than for
the prepared oligomers (55.6 ± 7.8%) even at 24 h.
Neurotoxicity and mitochondrial membrane potential
It could be speculated that the release of oAβ leading to cell-to-cell
transfer is caused by prior cell toxicity events. Thus, we investigated
the effect of the different oAβ species on both cell viability and mito-
chondrialmembrane stability and toxicity. An XTT assaywas performed
to determine the effect of oAβ isoforms on neuronal cell viability over
time. The results did not reveal any signiﬁcant difference in cell viability
asmeasured by the XTT assay performed on donor cells having internal-
ized 1 μMof any oAβ isoformover 72 h (Fig. 7A). Because the XTT assay
reports cell death and/ormitochondrial toxicity, these data indicate that
therewasno signiﬁcant cell death ormitochondrial toxicity upon the ly-
sosomal accumulation of oAβ. Furthermore, the mitochondrial mem-
brane potential was measured using a JC-1 assay. This assay did notshow any signiﬁcant mitochondrial toxicity at the time point (24 h)
when transfer of oAβwas already abundant and abnormally large lyso-
somes had started to appear in donor and acceptor cells (Fig. 7B). We
have previously reported the presence of organelle toxicities after lon-
ger periods of time with accumulated transferred oAβ1–42 (Nath et al.,
2012). Together with the present results, the data suggest that cell-to-
cell transfer is not secondary to cytotoxicity but that cellular transfer
might be an early stress response by the cell to rid itself of intracellular,
non-degradable, aggregation-prone accumulations.
Discussion
This study shows that different ﬂuorescently labeled Aβ-isoforms
(1–42, 1–40, 3(pE)–40 and 11–42) can transfer fromone cell to another.
Thus, cell-to-cell transfer is not dependent on a particular Aβ isoform,
but the net amount of any isoform in the receiving cell is vastly variable
because of differences in the capacity to clear and/or degrade these Aβ
isoforms. Hence, insufﬁcient clearance and/or degradation by cells cre-
ate sizable intracellular accumulations of the Aβ1–42 isoform, promoting
Fig. 6. Effects ofmonomers, dimers, oligomers and protoﬁbrils of Aβ1–42TMR on cell-to-cell transfer. (A) Separation ofmonomers, dimers and oligomers from the prepared oAβ1–42TMRby
SEC; n = 3. (B) Formation of a high number of extra-large lysosomal vesicles (marked with white arrows) in dimers and oligomers of oAβ1–42TMR transferred acceptor cells after 48 h.
Scale bar = 5 μm; n = 3. (C) Monomers of Aβ1–42TMR formed signiﬁcantly lower accumulations and signiﬁcantly lower extra-large lysosome formations compared to dimers and olig-
omers; n = 3. (D) The EM images showed that the prepared protoﬁbrils of Aβ1–42TMR are a mixture of oligomers, protoﬁbrils (black arrows) and ﬁbrils. Scale bar = 200 nm. (E) The
prepared protoﬁbrils disappeared signiﬁcantly (85–91%) in donor cells after 48 h. Scale bar = 10 μm. Data are calculated from ~50 cells for each isoform and are represented as the
means ± SEM. Statistical signiﬁcance was evaluated using a two-tailed unpaired Student's t test. *p b 0.05, **p b 0.01 and ***p b 0.001.
Fig. 7. Cytotoxicity. No cytotoxicity or mitochondrial toxicity was detected in donor cells in-
ternalized with 1 μmof the respective oligomeric isoforms over time. (A) No oligomeric iso-
form affected XTT processing compared to controls. (B) Mitochondrial potential was
quantiﬁed with ﬂow cytometry using a JC-1 assay, but no alterations were observed when
comparing the Aβ-isoforms and the control. Data are represented as the means ± SD;
n = 3.
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This study explains why the factors affecting clearance and/or degrada-
tion can have a strong impact on AD development.
Electron microscopic analysis of the oAβ preparations revealed that
all isoforms weremainly oligomeric in structure. The results are consis-
tent with previous reports showing that the Aβ1–42 isoform propagates
faster, forming larger-sized oligomers compared to the Aβ (1–40,
3(pE)–40, 11–42) isoforms (Ahmed et al., 2010). The characterizations
of the oAβs and the effect of TMR tagging were performed in vitro;
thus, their in vivo properties can only be inferred. However, we have
previously shown similar cytotoxicity with both TMR-labeled and unla-
beled oAβ1–42 (Nath et al., 2012). The oligomers of all of the oAβ-TMR
isoforms were spontaneously internalized by neuronal cells from the
extracellular space, accumulating mainly (65–85%) inside the late-
endosomes/lysosomes immediately after internalization. Previous stud-
ies using Aβ1–42 and Aβ1–40 showed similar late-endosomal/lysosomal
co-localization using lysotracker (Hu et al., 2009; Umeda et al., 2011).
These data suggest that intracellular internalization from the extracellu-
lar space is independent of Aβ isoform, at least in a model using only
partly differentiated cells.
Recent studies have reported the accumulation of Aβ peptides in ly-
sosomes/endosomes (Zheng et al., 2011), endoplasmic reticulum and
mitochondria (Umeda et al., 2011). The toxicity induced by Aβ from in-
tracellular accumulation is starting to be acceptedwidely in the AD ﬁeld
(Gouras et al., 2010; LaFerla et al., 2007;Wirths et al., 2001). In our pre-
vious study, the accumulation of internalized oAβ1–42TMR from the ex-
tracellular spacewas observed in structures corresponding to vesicles of
late-endosomes/lysosomes in both the donor and connector acceptor
cells (Nath et al., 2012). In the present study, the accumulation of inter-
nalized oAβ1–42TMR in lysosomes over time resulted in abnormally
91J. Domert et al. / Neurobiology of Disease 65 (2014) 82–92sized lysosomal vesicles in the donor and acceptor cells compared to ly-
sosomes that had internalized more degradable isoforms, including
oAβ11–42TMR, oAβ1–40TMR and oAβ3(PE)–40TMR. The increased expres-
sion of LAMP-2 with time in the donor cells after oAβ1–42TMR internal-
ization indicates the induction of cellular starvation and stress due to
intra-lysosomal accumulations of non-degradable oAβ1–42TMR. Inter-
estingly, this lysosomal stress was not paralleled by mitochondria-
associated toxicity at early time points, at least as revealed by the mito-
chondrial potential and XTT assays. Selective lysosomal toxicity in early
AD-like pathology has been reported previously (Lee et al., 2011a). This
result implies that cell-to-cell transfer is initiated before cytotoxicity de-
velops. Longer periods of oAβ1–42 transfer have been shown to cause
endosomal leakage and cytoskeletal damage (Nath et al., 2012). Thus,
our results suggest that cellular transfer might be an early stress re-
sponse by cells to get rid of intracellular, non-degradable, toxic accumu-
lations. These results could also explain how seeds for AD pathology
could pass on to newbrain areas before theﬁrst cell starts to deteriorate.
Oligomers of different Aβ-isoforms (1–42, 1–40, 3(pE)–40 and 11–
42) can all transfer from cell to cell. Thus, this transfer is not dependent
on a particular Aβ isoform, but the net amount ending up in the receiving
cell is vastly variable. There was a strong linear correlation between how
well the cells were able to clear and/or degrade the respective oAβ and
the number of connected acceptor cells containing transferred oAβ-
TMRs. The aggregation-prone isoformoAβ1–42TMRwas found to transfer
from donor cell to connected acceptor cells as previously shown (Nath
et al., 2012), and the number of acceptor cells with transferred oligomers
increased signiﬁcantly over time. The oAβ3(pE)–40TMR isoform showed a
partial resistance to clearance and/or degradation leading to moderate
transfer as compared to the oAβ1–42TMR isoform. Thisﬁnding is in agree-
ment with Aβ3(pE)–40 alone being moderately toxic in AD pathology
(Russo et al., 2002). However, adding oAβ1–40TMR or oligomers of non-
amyloidogenic oAβ11–42TMR (Janget al., 2013), both susceptible to clear-
ance and/or degradation by cells, to donor cells resulted in insigniﬁcant
accumulation in and insigniﬁcant transfer to the connected acceptor
cells. The latter ﬁnding is consistent with oAβ11–42TMR only showing
some toxic properties when modiﬁed at the N-terminal amino acid
with pyroglutamate (Jang et al., 2010, 2013). As in the different Aβ-
isoform oligomers, the isolated monomers, dimers and oligomers from
the oAβ1–42TMR also participated in cell-to-cell transfer according to
their lysosomal accumulations. Puriﬁedmonomers and dimers are high-
ly unstable and can propagate further to form higher oligomers. Mono-
mers are not neurotoxic, and the monomer-to-dimer transition is a
slow process that happens only under certain favorable environments
(Nag et al., 2011). However, dimers have been reported to be potential
seeds that accelerate propagation to form higher aggregates (Shankar
et al., 2008). Thus, the lag phase for the aggregation process should be
longer for monomers, and the monomeric Aβ will be more susceptible
to degradation compared to the dimers and oligomers. As a result, less
accumulation will occur with comparatively slower aggregating mono-
meric species. In concert with the ﬁndings for the other degradable iso-
forms, including oAβ1–40 and oAβ11–42, oAβ1–42, monomers have a
lower net transfer, and the formation of extra-large lysosome vesicles
is signiﬁcantly lower. Because only the net remaining Aβ can cause
seeding and pathology in the acceptor cells, these results may explain
why the aggregation-prone and less degradable oAβ1–42 is a highly
toxic species. The proﬁbrils of Aβ1–42, which were prepared differently
from the oligomers, consisted of a mixture of oligomers, protoﬁbrils
and ﬁbrils. Fibrillization of Aβ1–42 is a progressive process and separation
of a distinct stable form is technically difﬁcult. The faster disappearance
kinetics of protoﬁbrils compared to oligomersmight explain the variable
stability with stochastically induced seeds produced differently.
Recent studies of other neurodegenerative non-prion proteins (e.g.,
tau,α-synuclein, huntingtin, etc.) have revealed similar cell-to-cell prop-
agation and prion-like pathology progression (Brundin et al., 2010; Lee
et al., 2010). Together, these studies and our data support the possibility
of similar, prion-like propagation in different neurodegenerativediseases (see Prusiner, 2012 for a review). Consistent with this sugges-
tion, recent studies on transgenic mice and primate models showed
the induction of Aβ aggregation and propagation of AD pathology from
both injected AD brain extracts (Meyer-Luehmann et al., 2006; Ridley
et al., 2006) and synthetic Aβ (Jucker and Walker, 2013; Stohr et al.,
2012). However, not all of these studies have been able to show the in-
duction of propagation by synthetic Aβ (Meyer-Luehmann et al., 2006).
Fibrils formed by synthetic Aβ are sensitive to protease degradation
and rarely show seeding capacity (Langer et al., 2011). Injecting rodent
Aβ seeds intowild typemice also failed to induce pathology propagation.
Rather, propagation seems to depend on the source of the exogenous Aβ
seeds in transgenic animal models (reviewed in Jucker and Walker,
2013). However, unlike Aβ, tauopathy and α-synucleinopathy can in-
duce pathology from exogenous seeds in wild-type mice (reviewed in
Jucker andWalker, 2013). In vitro, Aβ forms polymorphic amyloid aggre-
gates. In contrast a recent study by Lu et al. (2013) showed the existence
of individually distinct Aβ ﬁbril conformations in AD patients, depending
on the type of AD pathology found. These results imply that the stochas-
tically induced multiple nucleated seeds in vivo could have been elimi-
nated by amyloid clearance mechanisms. However, individuals with
decreased clearance efﬁciency could have failed to degrade a particular
type of seeds leading to propagation of pathology with distinct Aβ ﬁbril
conformations (Lu et al., 2013), similar to the results seen in our study.
In the human brain, degradation and clearance of toxic products such
as non-degradable seeds are accomplished by neurons in concert with
glial cells. Therefore, intracellular accumulations and their progression
from small amounts of non-degradable seeds may take years before
causing pathology.
Conclusion
The progressions of toxic seeds of Aβ to connected cells and their
catalyzing effect to induce further aggregates, similar to the pathology
observed with prions, have been addressed in several studies
(Nussbaumet al., 2012; Stohr et al., 2012). The role of Aβ seeds in nucle-
ation and aggregation is a well-established fact, but the prion theory for
pathology propagation ignoresmany other inﬂuencing factors in the AD
etiology (Lahiri, 2012). Many of these factors inﬂuence cellular clear-
ance or degradation systems and have a strong inﬂuence on AD pathol-
ogy. These factors include dietary cholesterol,metabolic disorders, ApoE
lipoprotein, low-density lipoprotein receptors and insufﬁcient lysosom-
al–proteosomal and insulin-degrading enzymes (Selkoe, 1997). Hence,
the strong correlation between failed clearance and/or degradation
with subsequent intracellular accumulation and cell-to-cell propagation
revealed in this study can explain how the prion model for AD progres-
sion can act together with factors that inﬂuence cellular clearance or
degradation systems in the development of AD.
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